NIFTY/NIPT is currently the most extensive and successful clinical application of NGS, with the global rising trend of precision medicine, the future demand of NGS applications in other field will for sure be vigorous. The product manager, Chia-Chun Hung, from Taiwan Gene Health indicates that Reproductive Medicine/Obstetrics and Oncology are the two most rapidly progress areas of the current global NGS clinical applications.
As the demand for IVF has grown year by year, NGS applications have also grown from the currently popular prenatal screening to pre-pregnancy screening/diagnosis, as an example, the popularization of Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD) will for sure revolutionize the reproductive Medicine field. For oncology applications, it contains hereditary tumor genetic testing, cancer medication evaluation (Co***nion Genetic Testing/Co***nion Diagnostics), liquid biopsy (ctDNA, ctRNA, and Exosome). In connecting with this global trend, Taiwan Gene Health has devotedly set these categories as its future objectives.
Assemble the Asia-Pacific Testing Hub by Rooting in Taiwan to Have the Whole Asia in View
Taiwan is located in the central zone of the Asia-Pacific region; it has a particularly favorable geographic position with Japan and South Korea (Northeast Asia) to the north, and the ASEAN 10 countries (Southeast Asia) to the south. Furthermore, it owns mature quality in medicine, BGI gene test technology, and service staff members that, Director Kuo points out, if all the superiority conditions of Taiwan can be well employed, then the whole Asia can be in reach, and therefore, can have Taiwan as the Asia-Pacific clinical gene testing hub. |
Home
